BioSpace News Archive

Rezolute, Inc., a clinical stage biopharmaceutical company dedicated to advancing targeted therapies for rare and metabolic diseases with serious unmet needs, announced that it has entered into a $30 million debt financing agreement with investment affiliates managed by SLR Capital Partners.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) filed two supplemental Biologics License Application (sBLA) submissions for PADCEV® (enfortumab vedotin-ejfv) for review as part of the Real-Time Oncology Review (RTOR) pilot program.

It’s spring allergy season and 50 million allergy sufferers are looking for relief from congestion and allergy-related sinus pain. Tivic Health® Systems Inc., a first-in-class bioelectronic health device company, developed a unique drug-free solution for allergy sufferers, ClearUP® Sinus Pain Relief.

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has entered into an agreement with MSD to initiate a Phase II combination trial of olinvacimab, an anti-VEGFR2 antibody, and KEYTRUDA® (pembrolizumab),

On April 16, 2021 , Suzhou Porton Biologics Ltd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO service, officially announced the closing of Series A funding round

This spring, shoppers can support St. Jude Children’s Research Hospital® while purchasing the perfect gifts for Mothers’ Day and Father’s Day.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for CA-4948, a first-in-class, small molecule inhibitor of IR

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2021 RBC Capital Markets Global Healthcare Conference, May 18-20, 2021 .

- RAGWITEK is now indicated to treat ragweed pollen allergy in children and adolescents five through 17 years of age, in addition to adults through 65 years of age - - Ragweed pollen is one of the most common allergens found in North America and affects approximately 23 million people in the U.S.1 -

Ibere Pharmaceuticals (the “Company”) today announced that, commencing April 19, 2021 , holders of the units sold in the Company’s initial public offering of 13,800,000 units at $10.00 per unit, completed on March 2, 2021 , may elect to separately trade the Class A ordinary shares and redeemable warrants included in the units.